Clinical Study
Influence of Anti-TNF and Disease Modifying Antirheumatic Drugs Therapy on Pulmonary Forced Vital Capacity Associated to Ankylosing Spondylitis: A 2-Year Follow-Up Observational Study
Table 2
Secondary outcomes. Intragroup changes of selected clinical variables.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DMARDs group, group receiving disease modifying antirheumatic drugs; anti-TNF + DMARDs group, group receiving antitumor necrosis factor agents + DMARDs; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functioning Index; 6MWT, six-minute walk test; SGRQ, St. George’s Respiratory Questionnaire. Quantitative variables are presented as medians (and ranges); qualitative variables are presented in number (%). values were obtained using Wilcoxon test comparing responses at 12 and 24 months with the baseline. Significant difference with two-factor ANOVA Friedman test . |